Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth

Molecular Cancer Therapeutics

Volumn 13, Issue 5, 2014, Pages 1067-1077

  Wu, Qiang ^a   Kohli, Manish ^a   Bergen III, H Robert ^b   Cheville, John C ^a   Karnes, R Jeffrey ^a   Cao, Hong ^b   Young, Charles Y F ^a   Tindall, Donald J ^a   McNiven, Mark A ^b   Donkena, Krishna Vanaja ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR1C2 PROTEIN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; AZADIRACHTA INDICA EXTRACT; BETA1 INTEGRIN; CALRETICULIN; FOCAL ADHESION KINASE; NIMBOLIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN; UNCLASSIFIED DRUG; PLANT EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AZADIRACHTA INDICA; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL GROWTH; CHROMATOGRAPHY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROMA; FLOW CYTOMETRY; FOCAL ADHESION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYALINE DEGENERATION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MOUSE; MTS ASSAY; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HUMAN; IC50; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TOXICITY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZADIRACHTA; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FOCAL ADHESIONS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; PLANT EXTRACTS; PLANT LEAVES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899889670     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0699     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Donkena KV, Yuan H, Young CY. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets 2010;10:402-10.
3. Aapro MS. Management of advanced prostate cancer in senior adults: the new landscape. Oncologist 2012;17 Suppl 1: 16-22.
4. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5.
5. Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med 2013;368:1458-9.
6. Ghafoor Q, Chetiyawardana A. Nail changes secondary to docetaxel chemotherapy: a case report. J Med Case Rep 2008;2:24.
7. Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, et al. Novel therapeutic approaches for the treatment of castrationresistant prostate cancer. J Steroid Biochem Mol Biol 2013;138C: 248-56.
8. Alberti C. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma. Eur Rev Med Pharmacol Sci 2013;17: 1658-64.
9. Meiyanto E, Hermawan A, Anindyajati. Natural products for cancertargeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev 2012;13:427-36.
10. Anyaehie UB. Medicinal properties of fractionated acetone/water neem [Azadirachta indica] leaf extract from Nigeria: a review. Niger J Physiol Sci 2009;24:157-9.
11. Bose A, Chakraborty K, Sarkar K, Goswami S, Chakraborty T, Pal S, et al. Neem leaf glycoprotein induces perforin-mediated tumor cell killing by T and NK cells through differential regulation of IFNg signaling. J Immunother 2009;32:42-53.
12. Goswami S, Bose A, Sarkar K, Roy S, Chakraborty T, Sanyal U, et al. Neem leaf glycoprotein matures myeloid derived dendritic cells and optimizes anti-tumor T cell functions. Vaccine 2010;28:1241-52.
13. Maity P, Biswas K, Chattopadhyay I, Banerjee RK, Bandyopadhyay U. The use of neem for controlling gastric hyperacidity and ulcer. Phytother Res 2009;23:747-55.
14. Priyadarsini RV, Murugan RS, Sripriya P, Karunagaran D, Nagini S. The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells. Free Radic Res 2010;44:624-34.
15. Roy S, Goswami S, Bose A, Chakraborty K, Pal S, Haldar A, et al. Neem leaf glycoprotein partially rectifies suppressed dendritic cell functions and associated T cell efficacy in patientswith stage IIIB cervical cancer. Clin Vaccine Immunol 2011;18:571-9.
16. Schumacher M, Cerella C, Reuter S, Dicato M, Diederich M. Antiinflammatory, pro-apoptotic, and anti-proliferative effects of a methanolic neem (Azadirachta indica) leaf extract are mediated via modulation of the nuclear factor-kB pathway. Genes Nutr 2011; 6:149-60.
17. Girotra P, Singh SK, Nagpal K. Supercritical fluid technology: a promising approach in pharmaceutical research. Pharm Dev Technol 2013; 18:22-38.
18. An BS, Kang JH, Yang H, Jung EM, Kang HS, Choi IG, et al. Antiinflammatory effects of essential oils from Chamaecyparis obtusa via the cyclooxygenase-2 pathway in rats. Mol Med Rep 2013;8: 255-9.
19. Ahn J, Lee H, Jang J, Kim S, Ha T. Anti-obesity effects of glabridin-rich supercritical carbon dioxide extract of licorice in high-fat-fed obese mice. Food Chem Toxicol 2013;51:439-45.
20. Posadas SJ, Caz V, Largo C, De la Gandara B, Matallanas B, Reglero G, et al. Protective effect of supercritical fluid rosemary extract, Rosmarinus officinalis, on antioxidants of major organs of aged rats. Exp Gerontol 2009;44:383-9.
21. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, et al. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J 2011; 13:365-77.
22. Vanaja DK, Grossmann ME, Cheville JC, Gazi MH, Gong A, Zhang JS, et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest 2009;27:264-72.
23. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, et al. Antiangiogenic effects and therapeutic targets of Azadirachta indica leaf extract in endothelial cells. Evid Based Complement Alternat Med 2012;2012:303019.
24. Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, et al. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther 2013;12: 2569-80.
25. Lagerstedt SA, O'Kane DJ, Singh RJ. Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem 2004;50:603-11.
26. Gong Y, Wang D, Dar JA, Singh P, Graham L, Liu W, et al. Nuclear export signal of androgen receptor (NESAR) regulation of androgen receptor level in human prostate cell lines via ubiquitination and proteasome-dependent degradation. Endocrinology 2012;153: 5716-25.
27. Cao H, Garcia F, McNiven MA. Differential distribution of dynamin isoforms in mammalian cells. Mol Biol Cell 1998;9:2595-609.
28. Ida CM, Vrana JA, Rodriguez FJ, Jentoft ME, Caron AA, Jenkins SM, et al. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun 2013;1:20.
29. Infusino GA, Jacobson JR. Endothelial FAK as a therapeutic target in disease. Microvasc Res 2012;83:89-96.
30. Wang Y, Cao H, Chen J, McNiven MA. A direct interaction between the large GTPase dynamin-2 and FAK regulates focal adhesion dynamics in response to active Src. Mol Biol Cell 2011;22:1529-38.
31. Hollosy F, Keri G. Plant-derived protein tyrosine kinase inhibitors as anticancer agents. Curr Med Chem Anticancer Agents 2004;4: 173-97.
32. Chakrabarti R, Robles LD, Gibson J, Muroski M. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines. Cancer Genet Cytogenet 2002;139: 115-25.
33. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011;108:13728-33.
34. Ji Q, Chang L, Stanczyk FZ, Ookhtens M, Sherrod A, Stolz A. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res 2007;67:1361-9.
35. Lechertier T, Hodivala-Dilke K. Focal adhesion kinase and tumour angiogenesis. J Pathol 2012;226:404-12.
36. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007;9:90-100.
37. Miyazaki T, Kato H, Nakajima M, Sohda M, Fukai Y, Masuda N, et al. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 2003;89:140-5.
38. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009;417:651-66.
39. Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, St-Arnaud R, Dedhar S. Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 1997;386:843-7.
40. Chiang WF, Hwang TZ, Hour TC, Wang LH, Chiu CC, Chen HR, et al. Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma. Oral Oncol 2013;49:534-41.
41. Audhya A, Desai A, Oegema K. A role for Rab5 in structuring the endoplasmic reticulum. J Cell Biol 2007;178:43-56.
42. Okano K, Yamamoto J, Kosuge T, Yamamoto S, Sakamoto M, Nakanishi Y, et al. Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. Clinicopathologic study of 152 first resection cases. Cancer 2000;89:267-75.
43. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 1999;86: 332-7.
44. Huang M, Lu JJ, Huang MQ, Bao JL, Chen XP, Wang YT. Terpenoids: natural products for cancer therapy. Expert Opin Investig Drugs 2012;21:1801-18.
45. Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Dev Ther 2012;6:371-84.
46. Cunningham D,Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non- Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817-26.
47. Akhila A, Rani K. Chemistry of the neem tree (Azadirachta indica A. Juss.). Fortschr Chem Org Nat 1999;78:47-149.
48. Paul R, Prasad M, Sah NK. Anticancer biology of Azadirachta indica L (neem): a mini review. Cancer Biol Ther 2011;12:467-76.
49. Gupta SC, Prasad S, Sethumadhavan DR, Nair MS, Mo YY, Aggarwal BB. Nimbolide, a limonoid triterpene, inhibits growth of human colorectal cancer xenografts by suppressing the proinflammatory microenvironment. Clin Cancer Res 2013;19:4465-76.
50. Gupta SC, Prasad S, Reuter S, Kannappan R, Yadav VR, Ravindran J, et al. Modification of cysteine 179 of IkBa kinase by nimbolide leads to down-regulation of NF-kB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents. J Biol Chem 2010;285:35406-17.